中文 / CN
Deutsch / DE
日本語 / JP
한글 / KR
Contact Us
菜单

Cell Culture Media

Standard and Custom Options for Biologics Development and Manufacturing

Cell culture medium is vital to biologics development and manufacturing, supporting robust cell growth and viability in vitro. Expertly balancing cost, performance, and quality, WuXi Biologics’ media nurture a variety of host cells with essential nutrients. Efficient formulation and broad compatibility across biologic modalities and process modes ensure a cost-effective solution.

Key Benefits at a Glance

Gain high titers with consistent product quality.

Ensure long-term reliability through a stable, multi-source supply chain.

Cut media costs by at least 40% without sacrificing performance.

Streamline scale-up, technology transfer, and regulatory readiness to avoid late-phase delays.

Connect with Our Experts

Standard Media, Ready to Go

WuXi Biologics’ standard media, HighProTM and MagniCHOTM, optimize growth and productivity in CHO cell lines. Both series offer off-the-shelf availability for added convenience across all cell culture processes and program stages. Both series deliver consistent, scalable performance:

  • HighPro series—Widely adopted for fed-batch processes. Includes HighPro 100, HighPro 200, HighFeed 1/2, and HighFeed B1/B2.
  • MagniCHO series—Outstanding with popular parental CHO cell lines. Includes MagniCHO, MagniCHO-HD, MagniCHO Feed1/2, and MagniCHO One-feed.

Compatible across CHO Lines

The use of different CHO cell lines across 72 projects demonstrates broad media compatibility.

The use of different CHO cell lines across 72 projects demonstrates broad media compatibility, which promotes utility across host systems. Designed for WuXia™ CHO cell lines, the HighPro and MagniCHO series are also compatible with other CHO cell lines, such as CHO-GS, CHO-S, and CHO-M.

Non-WuXia cells require no protocol modifications or other adaptions, delivering plug-and-play utility across diverse upstream processes and strengthening implementation reliability. Performance is consistent across manufacturing sites and vendors, simplifying technology transfers and minimizing risk while accelerating scale-up and commercialization.

Multi-Source Reliability

Relying on catalog media from a single supplier can delay timelines, disrupt supply, and complicate compliance. To mitigate, WuXi Biologics implements a multi-source supply strategy that delivers reliable, high-quality supply with enhanced stability. We apply rigorous quality standards across all qualified manufacturers to maintain consistency and reduce supply chain risk.

By engaging multiple suppliers, we gain greater flexibility with faster lead times, seamless technology transfers, and tighter alignment to development milestones. Production scales efficiently and sourcing readily adjusts to shifting timelines and geographic priorities.

To further enhance operational flexibility, our standard media is globally accessible through approved vendors.

Global Trust Grounded in Compliance

Compared to other top-level catalog media, the HighPro and MagniCHO series support faster, more secure progression through regulatory pathways. To ensure global compliance, our standard media offer:

  • Comprehensive documentation, including Certificates of Analysis and animal-derived component-free statements
  • Drug Master File support, facilitating IND and BLA submissions
  • Enhanced quality control with extended stability data and lot-to-lot consistency testing

All documentation aligns with requirements from FDA, EMA, NMPA, TGA, and other global regulatory agencies, fast-tracking approvals in key markets. A multi-year production history backs GMP-compliant manufacturing.

Seventy-two representative projects across the biologics development spectrum highlight the scalability and regulatory readiness of WuXi Biologics’ standard media.

Custom Media Tailored for You

We tailor our custom media to fit biologics programs that require precise performance beyond platform standards. Whether you are working with novel hosts, complex molecules, or advanced process strategies, we optimize the formulation to suit your specific goals.

Spanning early development through commercial production, our custom media development service offers:

  • Media cost reduction of 40% or higher
  • Streamlined study design for faster results
  • Simultaneous optimization of multiple attributes
  • Understanding of key attributes affecting productivity and product quality

Predictive Formulation Optimization

Before lab work begins, predictive modeling forecasts how different medium formulations will perform. This virtual, data-driven screening is highly precise, enabling targeted modifications to key attributes—typically achieved in only 2 or 3 study rounds, with fewer than 20 conditions per round.

WuXi Biologics goes beyond traditional statistical approaches by pinpointing the media components that drive productivity gains and enable meaningful process optimizations.

Real-World Data

Increased productivity by 78%

Reduced media cost per gram by 63%

Obtained results in only 3 rounds of formulation development

Proven Formulations with Rapid Screening

WuXi Biologics leverages a culture medium library of basal and feed media to accelerate screening and customize formulation selection for your cell line. Detailed growth and performance data guide decision-making, helping you reach target titer and quality in only 1 to 2 months.

Speed

Complete high-throughput screening in less than 4 weeks.

Flexibility

Access a library of over
100 verified formulations.

Quality

Maintain comparable product quality attributes (PQAs).

Attribute-Specific Media Development

WuXi Biologics has synthesized extensive data on media components and how they influence PQAs into a toolbox that boosts quality and supports regulatory compliance. It provides deep insight into how media formulations shape the properties and performance of biologics, enabling precise adjustments to media components and additives.

Within only 1 or 2 study rounds, WuXi Biologics optimizes biologic products to meet defined quality specifications.

Medium Matters

Overcome the common challenges of biologics development and manufacturing:
low titers, inconsistent yields, high costs, slow timelines, regulatory roadblocks,
and limited flexibility in scaling, modality, and host system.

Contact Our Experts Today

Related Resources

[White Paper] Systematic Strategy to Reduce the Cost of Goods Sold

Download Now

[Service Overview] Cell Line Development

Download Now